These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24142600)

  • 1. A meta-analysis of clinical therapeutic effect of insulin glargine and insulin detemir for patients with type 2 diabetes mellitus.
    Zhuang YG; Peng H; Huang F
    Eur Rev Med Pharmacol Sci; 2013 Oct; 17(19):2566-70. PubMed ID: 24142600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
    Kvapil M
    Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
    Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness and harms of long-acting insulins for type 1 and type 2 diabetes: A systematic review and meta-analysis.
    Holmes RS; Crabtree E; McDonagh MS
    Diabetes Obes Metab; 2019 Apr; 21(4):984-992. PubMed ID: 30552792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L; Kesavadev J; Demissie M; Nazeri A; Hollander P
    Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?
    Wallace JP; Wallace JL; McFarland MS
    Ann Pharmacother; 2014 Mar; 48(3):361-8. PubMed ID: 24396092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
    Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir.
    Dailey G; Admane K; Mercier F; Owens D
    Diabetes Technol Ther; 2010 Dec; 12(12):1019-27. PubMed ID: 21128849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of insulin detemir versus glargine in patients with diabetes: a systematic review and meta-analysis.
    Rezaei S; Taheri A; Taheri S; Kasirzadeh S; Fatemi B; Sorato MM
    Expert Rev Clin Pharmacol; 2022 Jun; 15(6):767-777. PubMed ID: 35579011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
    Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
    J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
    King AB
    Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
    Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
    J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.
    Renard E; Dubois-Laforgue D; Guerci B;
    Diabetes Technol Ther; 2011 Dec; 13(12):1213-8. PubMed ID: 21810024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.
    Swinnen SG; Dain MP; Aronson R; Davies M; Gerstein HC; Pfeiffer AF; Snoek FJ; Devries JH; Hoekstra JB; Holleman F
    Diabetes Care; 2010 Jun; 33(6):1176-8. PubMed ID: 20200301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.